GlassScriptPhysician profile
David A Louis
NPI 1417042953
$1,711.01
in general payments reported to CMS, 2019-2025
23 companies · $189 in 2025
The $189 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $116 · 2021: $198 · 2022: $22.02 · 2023: $500 · 2024: $244 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $932.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $268.46 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $228.85 | 2019-2023 | |
| Gilead Sciences, INC. | $217.60 | 2019-2023 | Vemlidy |
| Novo Nordisk INC | $128.71 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $128.07 | 2024 | Dupixent |
| Amgen INC. | $125.51 | 2023-2025 | Tavneos, Prolia, Evenity |
| Astrazeneca Pharmaceuticals LP | $75.28 | 2019-2023 | Breztri |
| Collegium Pharmaceutical, INC. | $68.24 | 2023 | Belbuca |
| Exact Sciences Corporation | $56.96 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $52.70 | 2019 | |
| Astellas Pharma US INC | $51.76 | 2023-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $43.98 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $41.89 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $31.68 | 2021 | |
| Abbvie INC. | $26.78 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $24.98 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $24.06 | 2019 | |
| Genzyme Corporation | $21.87 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.69 | 2025 | Xifaxan |
| Sanofi-Aventis U.S. LLC | $19.68 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.67 | 2020 | |
| Electromed, INC. | $19.19 | 2024 | Smartvest |
| Advanced Respiratory, INC | $14.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Louis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.